Home/Aldeyra Therapeutics/Deanna D. Mosley

DD

Deanna D. Mosley

Scientist/Author

Aldeyra Therapeutics

Therapeutic Areas

Ophthalmology Immunology Rare Diseases Metabolic Diseases

Aldeyra Therapeutics Pipeline

Drug	Indication	Phase
Reproxalap	Dry Eye Disease (Signs & Symptoms)	Phase 3
ADX-2191	Primary Vitreoretinal Lymphoma	Phase 3 (likely)
ADX-629	Systemic Immune-Mediated & Metabolic Diseases	Phase 1/Phase 2 (implied)

Leadership Team at Aldeyra Therapeutics

Appears as Senior Author/Executive (likely CEO/CSO)

Clinical Investigator/Author

Clinical Investigator/Author

Clinical Investigator/Author

Scientist/Author

Christopher E. Starr

Clinical Investigator/Author

Kelly K. Nichols

Clinical Investigator/Author

Clinical Investigator/Author

Kenneth J. Mandell

Clinical Investigator/Author

Clinical Investigator/Author

View full Aldeyra Therapeutics profile